Quantitative assessment of quality of life in New Zealand prostate cancer survivors: the effect of androgen deprivation therapy
Journal Title: Journal of Cancer Research & Therapy - Year 2013, Vol 1, Issue 2
Abstract
Men with prostate cancer experience many challenges to their quality of life (QOL). While some of these challenges reflect the direct effects of the cancer, additional side-effects and symptoms are also associated with common treatments especially androgen deprivation therapy (ADT). While several studies have examined the effects of ADT on the QOL of men with prostate cancer, much of this research is between 10-20 years old and was conducted in North America or Europe. This study therefore examined the effects of ADT on QOL in prostate cancer patients (survivors) in the Southern hemisphere. The registries of two New Zealand based hospitals were sourced to identify men with prostate cancer who were using ADT for at least six months (ADT group, n=205) and those who had never used ADT (non-ADT group, n=143). Participants in both groups were mailed a letter of invitation, the WHOQOL-BREF and three facets of the WHOQOL-OLD QOL questionnaire. Response rates of 41% and 40% were obtained for the ADT and non-ADT groups, respectively. QOL scores were generally similar between the groups, with the exception of physical QOL, which was significantly lower in the ADT group. Such results suggest that cancer clinicians, allied health professionals and cancer researchers should not just concentrate on the physical effect of ADT on their survivors’ risk of developing osteoporosis, falls-related fracture and cardio-metabolic syndrome, but also devote time to ensure their survivors’ perception of their physical QOL is not compromised.
Authors and Affiliations
Keogh JW, Krägeloh CU, Shepherd D, Ryan C, Masters J, Osborne S, MacLeod R
Keywords
Related Articles
- EP ID EP550717
- DOI 10.14312/2052-4994.2013-16
- Views 65
- Downloads 0
Plant-based omega-3 stearidonic acid enhances antitumor activity of doxorubicin in human prostate cancer cell lines
Doxorubicin (DOX) is a first choice cytostatic drug in treatment of many cancers but among its side effects is cardiac toxicity. Stearidonic omega-3 fatty acid (SDA) has cardiac protective qualities and, therefore, we in...
Characterizing tobacco use in an American cancer center’s catchment area can help direct future research priorities
Purpose: American cancer centers supported by the National Cancer Institute (NCI) must ensure that their research addresses the cancer relevant needs and risks of members of their catchment area. In 2016, the NCI support...
Development of a new formulation of interferons (HEBERPAG) for BCC treatment
Purpose: This work is aimed to show briefly, the clinical development of a new pharmaceutical formulation of interferons for the treatment of basal cell carcinoma. Methods: A rationale design of the combination of IFN-α2...
Synergistic antineoplastic action of 5-aza-2'deoxycytidine (decitabine) in combination with different inhibitors of enhancer of zeste homolog 2 (EZH2) on human lung carcinoma cells
Patients with metastatic lung cancer have a very poor prognosis indicating an urgent need to develop more effective chemotherapy. Aberrant promoter DNA methylation can result in the epigenetic silencing of tumor suppress...
Changing clinical picture of endemic Burkitt’s lymphoma with improved diagnostic technology: A systematic review
We evaluated the changes in anatomical locations of endemic Burkitt’s lymphoma (eBL) by systematic review. We compared the reports before ultrasound became a routine investigation in Burkitt’s lymphoma (BL) diagnosis wit...